Mancuso, Renzo http://orcid.org/0000-0002-7046-3348
Fattorelli, Nicola
Martinez-Muriana, Anna http://orcid.org/0000-0002-8645-1317
Davis, Emma http://orcid.org/0000-0001-5820-6333
Wolfs, Leen
Van Den Daele, Johanna
Geric, Ivana http://orcid.org/0000-0002-6184-0594
Premereur, Jessie
Polanco, Paula
Bijnens, Baukje http://orcid.org/0000-0003-3890-5916
Preman, Pranav
Serneels, Lutgarde
Poovathingal, Suresh
Balusu, Sriram
Verfaillie, Catherine http://orcid.org/0000-0001-7564-4079
Fiers, Mark
De Strooper, Bart http://orcid.org/0000-0001-5455-5819
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (CELLPHASE_AD, XenoMicrogliaAD)
Fonds Wetenschappelijk Onderzoek (G0C9219N, G0K9422N, 1139520N, 12ZX621N, 1122423N)
Alzheimer’s Association (AARF-20-684397)
Universiteit Antwerpen (FFB210307)
Article History
Received: 28 November 2022
Accepted: 14 February 2024
First Online: 27 March 2024
Competing interests
: B.D.S. is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. B.D.S. is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. R.M. has scientific collaborations with Alector, Nodthera and Alchemab, and Roche, and has been a consultant for Sanofi. I.G. and L.W. are currently employed by Muna Therapeutics but were part of the De Strooper lab when this work was performed. The remaining authors declare no competing interests.